SWTX Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SpringWorks Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.02 |
| 52 Week High | US$53.92 |
| 52 Week Low | US$20.19 |
| Beta | 0.79 |
| 11 Month Change | 36.39% |
| 3 Month Change | -5.18% |
| 1 Year Change | 79.40% |
| 33 Year Change | -43.02% |
| 5 Year Change | 71.07% |
| Change since IPO | 72.43% |
Recent News & Updates
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results
Nov 15
SpringWorks Therapeutics Merits A Speculative Buy
Nov 04Recent updates
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results
Nov 15SpringWorks Therapeutics Merits A Speculative Buy
Nov 04SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15Shareholder Returns
| SWTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.1% | -3.7% | 0.3% |
| 1Y | 79.4% | 15.2% | 31.1% |
Return vs Industry: SWTX exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: SWTX exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| SWTX volatility | |
|---|---|
| SWTX Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SWTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SWTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 305 | Saqib Islam | www.springworkstx.com |
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas.
SpringWorks Therapeutics, Inc. Fundamentals Summary
| SWTX fundamental statistics | |
|---|---|
| Market cap | US$2.70b |
| Earnings (TTM) | -US$275.16m |
| Revenue (TTM) | US$135.49m |
21.4x
P/S Ratio-10.5x
P/E RatioIs SWTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SWTX income statement (TTM) | |
|---|---|
| Revenue | US$135.49m |
| Cost of Revenue | US$7.42m |
| Gross Profit | US$128.07m |
| Other Expenses | US$403.23m |
| Earnings | -US$275.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.70 |
| Gross Margin | 94.52% |
| Net Profit Margin | -203.09% |
| Debt/Equity Ratio | 0% |
How did SWTX perform over the long term?
See historical performance and comparison